

## References

### I-216

1. Selling ASK, Harslof T, Langdahl B. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. *Ther Adv Musculoskel Dis.* 2018;10(5- 6):105-115.
2. Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation, 2014.
3. Barrioneuvo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. *J Clin Endocrinol Metab.* 2019;104(5):1623-1630.
4. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. *J Clin Endocrinol Metab.* 2020;105(3):587-594.
5. Jeremiah MP, Unwin BK, Greenawald MH, et al. Diagnosis and management of osteoporosis. *Am Fam Physician.* 2015;92(4):261-268.
6. Dhesy-Third S, Fletcher GG, Blanchette PS, et al: Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol.* 2017;35(18):2062-2081.
7. Evenity (romosozumab) injection, for subcutaneous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 04/2020.
8. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Romosozumab. 2020.
9. Micromedex®Solutions Compendia. 2020. Romosozumab.
10. Romosozumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated June 8, 2020.
11. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.